Vascular endothelial growth factor receptor 3 is a novel marker differing CD138-positive and CD138-negative multiple myeloma cells

Br J Haematol. 2018 Jun;181(6):840-843. doi: 10.1111/bjh.14706. Epub 2017 May 16.

Authors

Maria N Kostjukova¹, Nikolai N Tupitsyn¹, Aida F Karamysheva²

Affiliations

¹ Laboratory of Haematopoiesis Immunology, Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Centre, Moscow, Russia.
² Laboratory of Tumour Cell Genetics, Institute of Carcinogenesis, N.N. Blokhin Russian Cancer Research Centre, Moscow, Russia.

PMID: 28508400
DOI: 10.1111/bjh.14706

No abstract available

Keywords: cell signalling; flow cytometry; multiple myeloma.

Publication types

Letter

MeSH terms

Biomarkers, Tumor / biosynthesis*
Female
Gene Expression Regulation, Neoplastic*
Humans
Male
Multiple Myeloma / metabolism*
Multiple Myeloma / pathology
Neoplasm Proteins / biosynthesis*
Syndecan-1*
Vascular Endothelial Growth Factor Receptor-3 / biosynthesis*

Substances

Biomarkers, Tumor
Neoplasm Proteins
SDC1 protein, human
Syndecan-1
FLT4 protein, human
Vascular Endothelial Growth Factor Receptor-3